Close Menu
    Facebook X (Twitter) Instagram
    ScoopSquare24
    • Home
    • News
    • AI
    • Crypto
    • Finance
    • Stocks
    Facebook X (Twitter) Instagram
    ScoopSquare24
    Home»News»Stocks»Macy’s Shares Surge 9% Following Strong Q4 Performance Despite Cautious Outlook
    Stocks

    Macy’s Shares Surge 9% Following Strong Q4 Performance Despite Cautious Outlook

    Oli DaleBy Oli DaleMarch 18, 2026No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    TLDR

    • Q4 adjusted earnings reached $1.67 per share, surpassing analyst expectations of $1.57
    • Quarterly sales totaled $7.64 billion, declining 1.7% annually but exceeding the $7.62 billion forecast
    • Same-store sales climbed 1.8%, crushing projections of a 0.9% drop
    • Shares rallied 9% during Wednesday’s premarket session following a 23% year-to-date decline
    • Fiscal 2026 EPS outlook of $1.90–$2.10 falls short of the $2.20 analyst consensus

    Macy’s (M) delivered fourth-quarter results that exceeded Wall Street projections on Wednesday, triggering a 9% premarket stock surge after months of market underperformance.

    Macy's Q4 2026 Earnings

    – Adj EPS $1.67 (est $1.54)

    – Total Rev. $7.92B (est $7.77B)

    – Net Sales $7.64B (est $7.51B)

    – Sees FY Net Sales $21.4B To $21.65B (est $21.11B)

    – Sees FY Adj EPS $1.90 To $2.10 (est $2.21)

    — First Squawk (@FirstSquawk) March 18, 2026

    The iconic retailer announced adjusted fourth-quarter profits of $1.67 per share, outpacing the Street’s $1.57 consensus estimate. Sales reached $7.64 billion, representing a 1.7% year-over-year decrease yet still topping analyst projections of $7.62 billion.


    M Stock Card
    Macy’s, Inc., M

    The year-over-year sales contraction stems primarily from strategic store closures executed during the previous fiscal year. Excluding these planned shutdowns reveals a healthier operational picture.

    Same-store sales — a critical retail indicator measuring locations open at least 12 months — increased 1.8%. This performance significantly exceeded analyst predictions of a 0.9% contraction and emerged as a standout metric in the quarterly report.

    CEO Tony Spring’s “Bold New Chapter” transformation initiative moved into year two, with continued emphasis on attracting affluent consumers. This strategic pivot manifested clearly across brand performance: the flagship Macy’s banner recorded modest 0.4% comparable sales growth, while Bloomingdale’s surged 8.5% and Bluemercury posted 2.5% gains.

    With shares down 23% prior to the earnings announcement, even moderate outperformance provided meaningful support.

    Guidance Falls Short

    For fiscal 2026, management projected net sales between $21.4 billion and $21.7 billion, with adjusted earnings per share ranging from $1.90 to $2.10. Wall Street had anticipated $21.42 billion in revenue and $2.20 in earnings per share.

    While the sales guidance brackets consensus expectations, the earnings forecast misses at both the midpoint and upper bound.

    Executives emphasized a “prudent approach” to their outlook, acknowledging macroeconomic uncertainty and geopolitical volatility. Consumer spending pressures persist, particularly affecting budget-conscious shoppers still grappling with elevated inflation.

    Ongoing store closures are projected to eliminate approximately $145 million in revenue this year. While anticipated, this drag remains significant.

    Tariff Impact Flagged for Q1

    Trade tariffs represent another critical variable in Macy’s planning. With substantial China-based sourcing, the company anticipates import duties will most severely impact margins during the first quarter of 2026 — the peak pressure window.

    Management indicated expectations for tariff headwinds to moderate during the year’s latter half. This perspective aligns with other major retailers, including Walmart and Kohl’s, which have similarly issued conservative annual projections.

    A Supreme Court decision established a universal 10% tariff rate, yet retailers with inventory purchased under higher duty structures continue facing near-term cost pressures as existing stock moves through channels.

    Retailers with significant Chinese supply chain exposure are closely monitoring Q1 performance. For Macy’s, this translates to a more challenging first half before potential relief materializes later in the year, assuming current assumptions hold.

    The fourth-quarter performance provided investors tangible reasons for optimism. Comparable sales grew 0.4% for the Macy’s brand, jumped 8.5% at Bloomingdale’s, and rose 2.5% at Bluemercury.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Oli Dale
    • Website

    Related Posts

    Circle Internet (CRCL) Hit with Class Action Lawsuit Over $280M Drift Protocol Breach

    April 17, 2026

    JPMorgan Analysts Say CLARITY Act Could Pass Before Midterm Elections

    April 17, 2026

    Tom Lee Predicts Further Gains After April 2026 Market Records

    April 17, 2026
    Leave A Reply Cancel Reply

    Breaking News
    Blockonomi

    Crypto News Just Turned Bullish: Coinbase CEO Brian Armstrong Calls a $60,000 Bitcoin Bottom While DOGE Holders Move to Pepeto

    Blockonomi
    Jun 16, 2026 9:27 PM
    Parameter

    CervoMed (CRVO) Stock Soars 32% on $3 Million Director Purchase

    Parameter
    Jun 16, 2026 8:27 PM
    Blockonomi

    CervoMed (CRVO) Surges 32% as Director Purchases $3 Million in Shares

    Blockonomi
    Jun 16, 2026 8:24 PM
    Moneycheck

    CervoMed (CRVO) Surges 32% Following Director’s $3 Million Stock Purchase

    Moneycheck
    Jun 16, 2026 8:24 PM
    Parameter

    Moderna (MRNA) Stock Surges 9% Following Positive FDA Assessment of mRNA Flu Vaccine

    Parameter
    Jun 16, 2026 8:20 PM
    Blockonomi

    Moderna (MRNA) Stock Surges 9% Following Positive FDA Review of mRNA Flu Vaccine

    Blockonomi
    Jun 16, 2026 8:17 PM
    Moneycheck

    Moderna (MRNA) Stock Surges 9% After FDA Gives Positive Signal on mRNA Flu Vaccine

    Moneycheck
    Jun 16, 2026 8:17 PM
    Coincentral

    CervoMed (CRVO) Stock Jumps 32% After Director Buys $3M – Time to Buy?

    Coincentral
    Jun 16, 2026 8:14 PM
    Parameter

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade from Underperform

    Parameter
    Jun 16, 2026 8:13 PM
    Blockonomi

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade to Peer Perform

    Blockonomi
    Jun 16, 2026 8:10 PM
    Moneycheck

    Palantir (PLTR) Stock Drops 2% Despite Wolfe Research Upgrade to Peer Perform

    Moneycheck
    Jun 16, 2026 8:10 PM
    Coincentral

    Moderna (MRNA) Stock Jumps 9% as FDA Clears Key Hurdle for mRNA Flu Shot

    Coincentral
    Jun 16, 2026 8:06 PM
    Coincentral

    Palantir (PLTR) Stock Falls 2% Even After Getting a Wall Street Upgrade

    Coincentral
    Jun 16, 2026 8:01 PM
    Blockonomi

    Anchorage Digital Unlocks New SWEEP Infrastructure for Institutions

    Blockonomi
    Jun 16, 2026 7:16 PM
    Parameter

    Alphabet (GOOG) Stock: Rises as Google Expands Android 17 Parental Controls

    Parameter
    Jun 16, 2026 7:13 PM
    Facebook X (Twitter) Instagram Pinterest
    ScoopSquare24

    Copyright © 2013 - 2026 Kooc Media Ltd. All rights reserved. Registered Company No.05695741
    Our Sites: FlowPresets / GardenBeast / GolfMonster / Blockonomi / Money Check / CoinCentral / Parameter / Circlo / Computing.net

    Type above and press Enter to search. Press Esc to cancel.